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Abstract: 
Alpha (α)-enolase (e), a glycolytic enzyme, has an alternative role as a surface receptor of several bacteria mediating plasminogen (pg) 
binding. It is also recognized as a virulence factor of some pathogenic bacteria facilitating plasminogen activation and host cell 
invasion. A mycoplasmal α-enolase is also a plasminogen binding protein. Molecular interactions of enolase from Mycoplasma 
pneumoniae with host plasminogen would be useful for exploring the pathogen-host interaction. In an attempt to identify plasminogen 
binding sites of M. pneumoniae enolase, homology modeling and docking studies were conducted to obtain modeled structures of the 
M. pneumoniae enolase-plasminogen complex. The refined model was validated further by standard methods. Molecular docking 
revealed hydrogen bonding of eLys70-pgTyr50, eAsn165-pgThr66, eAla168-pgGlu21, eAsp17-pgLys70, and eAsn213-
pgPro68/pgAsn69. Substantial decreases in accessible surface area (ASA) were observed and in concurrence with hydrogen bond 
pattern. These findings provide a detailed prediction of key residues that interact at the protein-protein interface. Our theoretical 
prediction is consistent with known biochemical data. The predicted interaction complex can be of great assistance in understanding 
structural insights, which is necessary to pathogen and host-component interaction. The ability of M. pneumoniae enolase to bind 
plasminogen may be indicative of an important role in invasion of this pathogen to host. 
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Background: 
Mycoplasma pneumoniae is one of the most commonly 
encountered pathogenic bacteria causing particular human 
diseases. Serious infections requiring hospitalization occur in 
both young adults and children. This pathogen infects not only 
pulmonary but also multiple organ systems. Extrapulmonary 
complications can occur in association with M. pneumoniae 
infection as a result of direct invasion especially central nervous 
system as encephalitis. Encephalitis manifestations are greater 
severity and more clinical importance than the primary 
respiratory infection. Over the past decades, the incidence of this 
bacterium invading CNS has increased dramatically [1, 2]. This 
trend may be partially due to several factors that contribute to 
the mistreatment, misdiagnosis, or mistreatment of patients as 
well as patient compliance, misuse of antimicrobial agents, and 
longer pathogen survival in the immuno-compromised host 
through antigenic mutations. Patients who suffer from persistent 
M. pneumoniae infection are a continuous transmission source 
to others in their community [3]. In fact, a number of recently 
developed therapies are no longer effective treatments [4]. 
Indeed, very little is known about the mechanisms underlying 
the virulence of this pathogen. A study of the mechanisms 
adopted by M. pneumoniae to invade and survive within host 
cells was carried out using confocal laser scanning microscopy 
indicating that M. pneumoniae has advanced mechanisms, which 
are not phagocytosis, for entering host cells [5]. It was suggested 
that Mycoplasma species invaded host cells by attaching to the 
surface of host cells and later cross the membrane into host cells 
[6]. A proposed mechanism, based on several studies, involved 
in pathogenesis is the interaction of bacterial cells with the 
human plasminogen system [7, 8]. A study demonstrated that 
Mycoplasma  fermentans was able to bind and activate 
plasminogen [9]. Similarly, plasminogen binding and activation 
were observed in M. pneumoniae  [8]. Host-derived plasmin 
activity is capable of dissolving fibrin meshes and extracellular 
matrices of the host cell, which facilitates bacterial entry [10]. 
Studies of α-enolase-plasminogen complexes have clearly 
shown that receptor-bound plasminogen is more readily 
converted to plasmin than free plasminogen [11, 12]. Enolase 
was characterized, by using competitive
  plasminogen binding 
assays and cross-linking studies
 with 
125I-labeled plasminogen 
and intact streptococci, as a plasminogen receptor on the surface 
of streptococci [11]. This investigation clearly showed that 
enolase significantly contributed to overall ability of 
Streptococcus to bind plasminogen. In a manner similar to that 
of streptococci, enolase mediated the binding of Candida 
albicans to plasminogen, which increased ability of cells in 
crossing  in vitro human brain microvascular endothelial cells 
[7]. Recently, there have been a number of reports indicating 
that enolase enhances the virulence of some pathogens [6]. The 
microbial enolase is captured by human plasminogen, and its 
subsequent conversion to plasmin provides a mechanism to 
augment virulence, favoring host tissue invasion [13, 14, 15]. 
For such action, enolase protein must be located on the surface 
of microbial pathogens [11, 15]. The matrix-assisted laser Bioinformation by Biomedical Informatics Publishing Group                               open access 
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desorption ionization-time of flight mass spectrometry (MALDI-
TOF MS) analysis of the peptide sequence of Streptococcus 
mutans  enolase revealed possibility of phosphorylation site(s) 
[15]. These findings suggested that enolase phosphorylation 
might occur and lead to its translocation to pathogen’s cell 
surface. In addition, immunogold bead staining supported the 
MALDI-TOF MS finding that enolase was detected on the 
surface of S. mutans [15]. The secreted enolase reassociates with 
the bacterial cell surface was confirmed by direct binding of 
radiolabeled recombinant protein to pneumococci and by field 
emission scanning electron microscopic analysis [13]. The M. 
fermentans α-enolase binding to plasminogen has recently been 
reported  [16]. In light of the above findings, this work is an 
attempt to predict molecular interaction of M. pneumoniae 
enolase with human plasminogen which would be useful for 
further investigation of the mechanism of M. pneumoniae 
invasion to human brain. 
 
 
Figure 1: Sequence alignment of Mycoplasma pneumoniae enolase (P75189) with Escherichia coli enolase (PDB ID: 1E9I) 
using CLUSTAL W. 
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Figure 3: Theoretical model of M. pneumoniae enolase. This model was conducted by MODELLER program. (a) Overall structure of 
M. pneumoniae enolase with containing Mg
2+ cofactor. (b) Comparison of enolase structure among three diferrent organisms.
 
Methodology: 
The protein sequence of M. pneumonaie enolase sequence was 
obtained from GenBank (Accession number P75189). Modeling 
templates were searched by using BLAST. In order to analyze 
modeled complex of protein-protein interaction, sequence 
identity of 40-50% between target and template may be 
required. Multiple sequence alignment was performed by using 
ClustalW. The atomic coordinates of Escherichia coli enolase 
was retrieved from Protein Data Bank, (PDB ID: 1E9I). 
Molecular structures of M. pneumonaie enolase were modeled 
by using restraint-based modeling implemented in the program 
MODELLER  [17]. Several models were generated and were 
then energy minimized using the molecular dynamics and 
simulation procedure CHARMM [18] in program MODELLER. 
The quality and stereochemistry of the models were evaluated 
using the program PROCHECK [19]. The final model was 
selected based on stereochemical quality. The main-chain 
conformations for 98.80% amino acid residues were within the 
favored or allowed regions of the Ramachandran plot and the 
overall G-factor was -0.11, indicating that molecular geometry 
of the model is of good quality. The selected model was then 
added Mg
2+ and further refined by energy minimization by the 
NAMD program (http://www.ks.uiuc.edu/Research/namd/) by 
2,000 steps of conjugate gradient minimization until the energy 
gradient RMS was < 0.05 kcal (mol Å)
-1. Structural models were 
visualized by PyMol™ Molecular Graphics System version 0.97 
(DeLano Scientific LLC, San Carlos, CA, USA, 
http://www.pymol.org). The VMD program was used to 
superimpose structure of M. pneumoniae enolase model with 
crystal structures of enolases from E. coli (PDB ID: 1E9I) [20] 
and  S. pneumoniae (PDB ID: 1W6T) [13].  M.  pneumoniae 
enolase model was docked to human plasminogen using Hex 4.5 
(http: //www.csd.abdn. ac.uk/hex/). The atomic coordinates of 
human plasminogen was retrieved from PDB (PDB ID: 1B2I) 
[21]. Automate energy minimization was applied to each 
docking solution. The Chimera program (http: //www.cgl.ucsf. 
edu/chimera/) was exploited to identify hydrogen bonds using 
default parameters and geometric criteria described previously 
[22]. Mark Gerstein's calc-surface program, which is 
implemented in the program Chimera, was used to calculate the 
solvent accessibility at the interface of M. pneumoniae enolase 
and human plasminogen before and after docking. 
 
 
Figure 4: Model of M. pneumoniae enolase-human plasminogen complex interaction. (a) H-bond represent in red line. (b) 
Electrostatic surfaces, a color ramp was calculated, which positive potential charges in blue, negative values in red, and intermediate 
values in white by using PyMol (http://pymol.sourceforge.net/). 
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Results and discussion: 
Template identification and model quality 
Crystal structures of enolases from many organisms, including 
those from bacteria, have already been determined and available 
in PDB [13, 20]. Based on sequence similarity analysis, M. 
pneumoniae enolase shows 55% amino acid sequence identity 
with Escherichia coli enolase (Figure 1). It is one of top ranks 
with high degree of sequence identities between M. pneumoniae 
enolase and other enolases with known structures. Practically, at 
this level of sequence identity, it is good enough to use 
crystallographic structures of E. coli enolase as a template, in 
order to obtain high quality alignment for structure prediction by 
homology modeling. An E. coli enolase crystal structure 1E9I 
[20] was specifically selected on the basis of BLAST result and 
was utilized as a template for M. pneumoniae enolase structure 
modeling. Structural models for M. pneumoniae enolase were 
built by MODELLER program [17] based on atomic coordinates 
of 1E9I and were then energy minimized. The model with the 
lowest objective function (348.7318), which was considered as 
the best one, was selected and subjected to quality evaluation. 
The PROCHECK Ramachandran plot analysis shows that the 
main-chain conformations for 98.80% of amino acid residues 
are within the most favored or allowed regions (Figure 2). The 
structural model of M. pneumoniae enolase is shown in Figure 
3a. The G-factors, indicating the quality of covalent and bond-
angle distance, were -0.07 for dihedrals, -0.22 for covalent, and 
overall -0.11. The overall main-chain and side-chain parameters, 
as evaluated by PROCHECK, are all very favorable. The 
comparable Ramachandran plot characteristic and G-factors 
confirm the quality of predicted model. The M. pneumoniae 
enolase model consists of typical two domains. The N-terminal 
one contains three-stranded antiparallel β-sheets, followed by 
six  α-helices. The C-terminal domain composes of eleven-
stranded mixed α/β-barrel with connectivity. The first α-helix 
within the C-terminal domain, H7, and the second β-strand, S7, 
of the barrel domain were arranged in an antiparallel fashion 
compared to all other α-helices and β-strands (Figure 3a). The 
RMSD (Root Mean Square Deviation) between predicted model 
and template is 0.4 Å (Angstrom). The overall conformation of 
M.  pneumoniae enolase model is similar to those of E.  coli 
enolase and S. pneumoniae enolase crystal structures [13, 20] as 
observed by the superposition analysis shown in Figure 3b. The 
Mg
2+, a metal ion cofactor, was encircled by Asp256, Glu310, 
and Asp337 which located in active site of enolase (Figure 3a). 
Although Mg
2+ is required for catalytic activity of the enzyme, it 
may also play a role in stabilizing enolase conformation [20]. 
 
Interaction of M. pneumoniae enolase and human 
plasminogen 
Based on rigid-body docking using HEX 4.5, both proteins were 
analyzed for shape complementary, hydrophobic effects 
resulting from a decrease in the solvent accessible surface, and 
electrostatic interactions. The key amino acid residues within the 
docking complex model involved in the interaction between 
enolase (e) and human plasminogen (pg) are eLys70-pgTyr50, 
eAsn165-pgThr66, eAla168-pgGlu21, eAsp17-pgLys70, and 
eAsn213-pgPro68/pgAsn69 (Figure 4a). These residues were 
determined based on intermolecular hydrogen bond lengths of 
amino acid residues interacted between human plasminogen and 
M. pneumoniae enolase. All hydrogen bond lengths appear to be 
shorter than 3.4 Å (Table 1 under supplementary material). This 
suggests that hydrogen bonds can be plausibly formed. The 
docking result indicated that the complex could be stabilized by 
hydrogen bonding. Electrostatic potential surface area showed 
that 10 amino acid residues of M. pneumoniae enolase appeared 
to be available for making contact with plasminogen (Figure 
4b). These also include eArg24, eLys70, and eLys216, positive 
charge residues located at the opposite end of the binding 
pocket. On human plasminogen molecule, several charge amino 
acid residues, including pgGlu21, pgAsp26, and pgAsp67, 
appeared in electrostatic potential surface area. Moreover, the 
decreases of accessible surface area (ΔASA) of the docking 
complex were observed Table 2a and Table 2b (see 
supplementary material). Considering M. pneumoniae enolase, 
significant change of accessible surface area of eLys70 
occurred. Noticeably, hydrogen bonding was observed on this 
residue. For human plasminogen on the complex, the model 
showed large decrease in accessible surface area involving 
residues pgGlu21, pgTyr50, pgAsp67, pgPro68, pgAsn69 and 
pgLys70. Some of these appeared to form hydrogen bonds with 
corresponding residues of M. pneumoniae enolase. The results 
suggest that model of the interaction complex between M. 
pneumoniae enolase and human plasminogen can be practicable. 
Our model of M. pneumoniae enolase-plasminogen complex 
was in agreement with the previous study lysine binding site 
(LBS) of plasminogen in terms of charge characteristics [23]. In 
addition, the proposed interaction between human plasminogen 
and M. pneumoniae enolase agreed with previous experimental 
investigations  [11, 12, 13]. The interaction between human 
plasminogen and M. pneumoniae enolase proposed in this study 
is useful for understanding the possible mechanism used by M. 
pneumoniae to invade human brain tissue. For instance, the 
interaction between human plasminogen  and  M. pneumoniae 
enolase might provide a vehicle for targeting cells. This line of 
work may lead to insight into host-pathogen interaction and 
provide valuable information for prophylactic strategies in 
combating infections at a very early stage.  
 
Conclusion:  
The rationale in building a M. pneumoniae enolase model and 
performing a binding study with human plasminogen is to gain 
details of interaction between the two proteins. M. pneumoniae 
enolase modeling was conducted using homology modeling. 
Comparison of the obtained model with experimentally derived 
crystal structures of E. coli enolase and S. pneumoniae enolase 
revealed that they were all basically similar. The docking studies 
revealed the important residues involving in the interaction of 
M. pneumoniae enolase with human plasminogen. Analyses of 
the interaction model between human plasminogen and M. 
pneumoniae enolase, based on distances of hydrogen bonds, 
changes of solvent accessible surface, electrostatic potentials, 
showed that this binding complex was reliable. Our theoretical 
prediction may lead to the establishment of prophylactic and 
therapeutic approaches.  
 
Acknowledgment:  
This research was supported by the Thailand Graduate Institute 
of Science and Technology (TGIST) scholarship TGIST 01-48-
039 from the National Science and Technology Development 
Agency (NSTDA). We would like to acknowledge Dr. Stefano 
O. Casalotti and Duangpon Wanapun for critical reading of the 
manuscript and Dr. Sudsanguan Chusacultanachai and Somchai 
Pongpattakitchote for helpful discussions.  
  Bioinformation by Biomedical Informatics Publishing Group                               open access 
www.bioinformation.net                                                              Hypothesis 
__________________________________________________________________________________ 
 
ISSN 0973-2063                                                                          
Bioinformation 3(1): 18-23 (2008) 
Bioinformation, an open access forum 
© 2008 Biomedical Informatics Publishing Group 
22 
References:  
[01]  M. Coelho et al.,  Clin. Neurol. Neurosurg., 106: 129 
(2004) [PMID: 15003304] 
[02]  A. Bitnun et al.,  Clin. Infect. Dis., 32:  1674 (2001) 
[PMID: 11360206] 
[03]  A. Wattanathum et al., Chest, 123: 1512 (2003) [PMID: 
12740268] 
[04]  S. Suzuki
 et al., Antimicrob. Agents Chemother., 50: 709 
(2006) [PMID: 16436730] 
[05]  A. Yavlovich et al.,  FEMS Microbiol. Lett., 233: 241 
(2004) [PMID: 15063492] 
[06]  V. Pancholi and G. S. Chhatwal, J. Med. Microbiol., 
293: 391 (2003) [PMID: 14760970]  
[07]  A. Y. Jong et al., J. Med. Microbiol., 52: 615 (2003) 
[PMID: 12867553] 
[08]  A. Yavlovich et al., Infect. Immunol., 72: 5004 (2004) 
[PMID: 15321992] 
[09]  A. Yavlovich et al., Infect. Immunol., 69: 1977 (2001) 
[PMID: 11254548] 
[10]  R. Lottenberg et al.,  Trend. Microbiol., 2: 20 (1994) 
[PMID: 8162432] 
[11]  V. Pancholi and V. A. Fischetti, J. Biol. Chem., 273: 
14503 (1998) [PMID: 9603964] 
[12]  A. Redlitz et al., Eur. J. Biochem., 227: 407 (1995) 
[PMID: 7851415] 
[13]  S. Bergmann et al.,  Mol. Microbiol., 40: 1273 (2001) 
[PMID: 11442827] 
[14]  D. Fox and A. G. Smulian, Med. Mycol., 39: 495 (2001) 
[PMID: 11798055] 
[15]  J. Ge et al., Infect. Immun., 72: 6748 (2004) [PMID: 
15501816] 
[16]  A. Yavlovich et al., Infect. Immunol., 75: 5716 (2007) 
[PMID: 17938226] 
[17]  A. Sali et al., Proteins, 23: 318 (1995) [PMID: 8710825] 
[18]  A. Sali and T. L. Blundell, J. Mol. Biol., 234: 779 (1993) 
[PMID: 8254673] 
[19]  R. A. Laskowski et al., J. Appl. Cryst., 26: 283 (1993) 
[PMID: 1579569] 
[20]  K. Kühnel and B. F. Luisi, J. Mol. Biol., 313: 583 (2001) 
[PMID: 11676541] 
[21]  D. N. Marti et al.,  Biochemistry,  38:  15741 (1999) 
[PMID: 10625440] 
[22]  J. E. Mills and P. M. Dean, J. Comput. Aided Mol. Des., 
10: 607 (1996) [PMID: 9007693] 
[23]  Y. Gong et al.,  J. Biol. Chem., 276: 19078 (2001) 
[PMID: 11264290] 
 
Edited by P. Kangueane 
                                              Citation: Chumchua et al., Bioinformation 3(1): 18-23 (2008) 
         License statement: This is an open-access article, which permits unrestricted use, distribution, and reproduction in  
                                         any medium, for non-commercial purposes, provided the original author and source are credited. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Bioinformation by Biomedical Informatics Publishing Group                               open access 
www.bioinformation.net                                                              Hypothesis 
__________________________________________________________________________________ 
 
ISSN 0973-2063                                                                          
Bioinformation 3(1): 18-23 (2008) 
Bioinformation, an open access forum 
© 2008 Biomedical Informatics Publishing Group 
23 
Supplementary material 
 
M. pneumoniae enolase  Human plasminogen  Distance (Å) 
Lys 70-NZ  Tyr 50-OH  2.68 
Asn 165-ND2  Thr 66-O  3.21 
Ala 168-O  Glu 21-N  3.21 
Asp 171-OD1  Lys 70-NZ  3.24 
Asn 213-ND2  Pro 68-O  1.93 
Asn 213-OD1  Asn 69-ND2  2.94 
Table 1: The distance between the modeled M. pneumoniae enolase and human plasminogen bound by hydrogen bonding. 
 
M. pneumoniae enolase amino acid residue  ASA of free 
M. pneumoniae enolase 
ASA of M. pneumoniae enolase + Plasminogen 
Arg 24  37.14  19.41 
Phe26 24.14  9.61 
Lys 70  22.96  4.08
 a 
Asn 165  0.94  0.94
a 
Ala 168  21.27  3.17
 a 
Asp171 38.34  38.34
 a 
Asn 213  23.43  23.43
a 
Thr214 25.05  25.05 
Asn215 33.49  33.49 
Lys216 19.44  19.44 
Asp218 5.84  5.63 
Table 2a: Accessible Surface Area (ASA) values of the amino acids of the M. pneumoniae enolase model that made contact or 
produced hydrogen bonding with human plasminogen. 
aHydrogen bond produced. 
 
Plasminogen amino acid residue  ASA of free Plasminogen  ASA of Plasminogen + M. pneumoniae enolase 
Glu21 21.81  3.45
 a 
Asp26 9.49  3.43 
Ser27 16.11  14.553 
Gln28 25.92  7.59 
Ser29 20.21  11.35 
Pro30 15.50  6.66 
Lys48 34.70  0.80 
Tyr50 18.76  4.13
a 
Thr66 21.35  21.09
 a 
Asp67 12.66  0.70 
Pro68 30.78  7.75
 a 
Asn69 40.05  20.20
 a 
Lys70 27.32  1.27
 a 
Table 2b: Accessible Surface Area (ASA) values of the amino acid of human plasminogen that made contact or produced hydrogen 
bonding with the modeled M. pneumoniae enolase. 
aHydrogen bond produced. 
 